Customer Service: 866-788-9007
×

David Kraljic

Castle Biosciences Added to NASDAQ Biotechnology Index

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Dec. 18, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that the Company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to the market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified …

Castle Biosciences Added to NASDAQ Biotechnology Index Read More »

Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations

Data was presented during the 16th International Congress of the Society for Melanoma Research FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 25, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data from an expanded, multi-center, prospectively tested patient cohort study supporting clinical use of the DecisionDx®-Melanoma test to …

Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations Read More »

Castle Biosciences to Present at Upcoming Investor Conferences

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 20, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences: Piper Jaffray 31st Annual Healthcare Conference, New York Presentation on Wednesday, December 4, 2019, at 2:30 p.m. EST Evercore ISI 2nd Annual HealthCONx …

Castle Biosciences to Present at Upcoming Investor Conferences Read More »

Castle Biosciences Reports Third Quarter 2019 Results

Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018 Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 2018 Q3 2019 gross margin increased to 88%, up from 64% in Q3 2018 December 2019 salesforce expansion Presented clinical validation data for DecisionDx-SCC Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, …

Castle Biosciences Reports Third Quarter 2019 Results Read More »

Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk

Data presented at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 31, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of results from a study validating a newly developed nomogram tool that combines information from the DecisionDx®-Melanoma test …

Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk Read More »

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 29, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of a development update and validation data for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC. The study titled, “Development and validation of a prognostic gene expression profile …

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting Read More »

Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 28, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the third quarter ended September 30, 2019, after the close of market on Monday, November 11, 2019. Company management will host a conference call and …

Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019 Read More »

Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Oct. 28, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data supporting clinical use of the DecisionDx®-Melanoma test to inform decisions of whether to discuss or recommend the sentinel lymph node biopsy (SLNB), a surgical procedure used to …

Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis Read More »

Scroll to Top